NanoTemper Introduces New Executive Leadership Team to Advance Biophysical Innovation
January 7, 2026The formation of the executive team marks a significant milestone as NanoTemper builds on its strong foundation of scientific excellence and customer-centered innovation to advance biophysical characterization solutions that simplify complex science and accelerate drug discovery. The NanoTemper executive leadership team is led by Stefan Duhr, Co-Founder and Chief Executive Officer, and includes: ● Eva …
NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman
October 15, 2024NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske and Stefan Duhr have redefined their roles to better position the company for continued growth and innovation. Stefan Duhr will now serve as the sole CEO, bringing sharper focus and agility to the execution of NanoTemper’s strategy. Philipp Baaske …
Expanding Access to Discovery by Building Biophysical Capabilities in Kenya
March 18, 2026In a laboratory at Masinde Muliro University of Science and Technology (MMUST), a new instrument is now ready for use. The Prometheus, a high-tech system for assessing protein stability, was officially received by Vice Chancellor Prof. Solomon Shibairo and significantly expands the University’s biophysical and biomedical research capabilities. For researchers and students who will use …
The Future of Molecular Analysis: Dr Stefan Duhr on NanoTemper’s Single-Molecule Vision
December 1, 2025Stefan Duhr, CEO of NanoTemper, talks about the new tech that reveals hidden molecular dynamics, and how the recent acquisition fits into the company’s overall vision. The journey from a biological target to an effective therapeutic is a marathon of meticulous decision-making. Each step in early-stage drug discovery relies on high-quality data to answer fundamental …
NanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market
October 14, 2024NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper Technologies’ commitment to fostering cutting-edge development while staying true to its mission – to create a world where every disease is treatable.
NanoTemper Technologies Establishes Advisory Board to Propel Innovation and Growth
July 12, 2024NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper Technologies’ commitment to fostering cutting-edge development while staying true to its mission – to create a world where every disease is treatable.
NanoTemper brings Spectral Shift technology to the protein production market with Andromeda X, enabling biopharma and CROs
May 6, 2024NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates.
NanoTemper Technologies announces Monolith X with breakthrough Spectral Shift technology, enabling binding affinity measurements where other methods fail
September 21, 2022NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
NanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine which protein labeling strategy works best for molecular interaction measurements
April 6, 2022NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help scientists more efficiently measure molecular interactions, a process that’s necessary to discover and develop new drugs.
NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
March 24, 2022NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery. This breakthrough technology removes the roadblocks experienced by scientists dealing with really complex molecular interactions often seen in challenging drugs and drug targets like Proteolysis-targeting chimeras (PROTACs), Intrinsically Disordered Proteins (IDPs), or fragment libraries.